This investigation revealed significant differential expression of CTU2 across 24 cancer types (Figure 1A), with fold changes exceeding 2 in diffuse large B-cell lymphoma (DLBC), thymoma (THYM), cholangiocarcinoma (CHOL), and glioblastoma multiforme (GBM) (Supplementary Table S1). Here, CTU2 is linked to cholangiocarcinoma.